目的 探讨参松养心胶囊联合瑞舒伐他汀对急性心肌梗死后心脏功能和早期心室重构的影响。方法 选取2016年1月—2018年2月汉中市中心医院进行诊治的急性心肌梗死患者88例作为研究对象，根据治疗方法的不同将患者分为对照组（40例）和观察组（48例）。对照组口服瑞舒伐他汀钙片，20 mg，1次/d。观察组在对照组基础上口服参松养心胶囊，4粒/次，3次/d。两组均治疗观察3个月。观察两组患者的临床疗效，同时比较两组患者的心功能指标、心室重构情况和主要心血管事件发生情况。结果 治疗后，观察组与对照组的总有效率分别为97.9%和87.5%，两组患者总有效率比较差异显著（P<0.05）。两组治疗后的左心室射血分数（LVEF）、左心室舒张期内径（LVDd）和左心室收缩期内径（LVDs）值显著高于治疗前（P<0.05），且观察组心功能指标水平明显高于对照组（P<0.05）。治疗后，观察组患者正性重构、无重构与负性重构例数分别为2例、18例与28例，而对照组分别为18例、10例、12例，对比差异有统计学意义（P<0.05）。治疗后随访6个月，观察组的主要心血管事件的发生率为8.3%，显著低于对照组的32.5%（P<0.05）。结论 参松养心胶囊联合瑞舒伐他汀治疗急性心肌梗死后能改善早期心室重构状况和心脏功能，从而提高患者的近远期疗效。

Objective To investigate the effects of Shensong Yangxin Capsules combined with rosuvastatin on cardiac function and early ventricular remodeling after acute myocardial infarction. Methods A total of 88 patients with acute myocardial infarction treated in Hanzhong Central Hospital from January 2016 to February 2018 were selected as research objects, and the patients were divided into control group (40 cases) and observation group (48 cases) according to different treatment methods. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 20 mg, once daily. Patients in the observation group were po administered with Shensong Yangxin Capsules on the basis of control group, 4 capsules/time, three times daily. Both groups were treated and observed for 3 months. The clinical efficacy in two groups was observed, and the cardiac function indicators, ventricular remodeling, and major cardiovascular events in two groups were compared. Results After treatment, the total effective rate of the observation group and the control group was 97.9% and 87.5%, respectively, with significant difference between the two groups (P<0.05). After treatment, the values of LVEF, LVDd, and LVDs in two groups were significantly higher than those before treatment (P<0.05), and the level of cardiac function indexes in the observation group was significantly higher than those in the control group (P<0.05). After treatment, the number of positive, non-reconstructive, and negative reconstructive patients in the observation group was 2, 18, and 28 cases, respectively, while those in the control group was 18, 10, and 12 cases, respectively, with statistically significant difference (P<0.05). After 6 months of follow-up, the incidence of major cardiovascular events in the observation group was 8.3%, significantly lower than 32.5% in the control group (P<0.05). Conclusion Shensong Yangxin Capsules combined with rosuvastatin in treatment of acute myocardial infarction can improve the early stage of ventricular remodeling and cardiac function, so as to improve the s efficacy of patients.

R972